"We found that being treated at an academic center was associated with improved survival, suggesting that specialized care for CMML is an important aspect of treatment." — Douglas Tremblay, MD, Tisch ...

– Complete remission (CR) rate of 50% and overall response rate (ORR) of 66.7% in 18 evaluable patients with CMML treated with IO-202 in combination with azacitidine – – CR rate of 83.3% and ORR of ...

By: Dr. Amrit Kaur Kaler For patients diagnosed with blood cancers such as leukemia, lymphoma, and multiple myeloma, the ...

This article is authored by Dr Amrit Kaur Kaler, consultant, molecular pathology, Kokilaben Dhirubhai Ambani Hospitals, ...

Adding venetoclax to oral decitabine-cedazuridine improves responses in higher-risk MDS and CMML patients. Inqovi, an oral decitabine-cedazuridine combination, was FDA approved in 2020 for primary or ...

(RTTNews) - Cardiff Oncology, Inc. (CRDF) has presented new clinical data from an investigator-sponsored Phase 1 dose escalation trial evaluating onvansertib, a novel oral PLK1 inhibitor, in patients ...